Recently, the he Category 1 innovative drug Bevifibatide Citrate Injection (trade name: 贝塔宁/BETAGRIN) of Bio-Thera Solutions, Ltd. is approved for marketing by China NMPA. This drug is indicated for patients with acute coronary syndrome who undergo percutaneous coronary intervention (including intracoronary stenting) to reduce the risk of acute occlusion, and in-stent thrombosis, as well as the occurrence of no reflow and slow flow.

Bevifibatide citrate, a peptide platelet GPIIb/IIIa (also known as αIIbβ3) receptor antagonist, inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands from binding to platelet GPIIb/IIIa receptors. The marketing of this drug provides a new antithrombotic treatment option for patients with acute coronary syndrome who require PCI treatment.